Opus Genetics, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- George Magrath
- Full Time Employees
- 28
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 8 Davis Drive Durham NC United States of America 27713
- IPO Date
- Jan 19, 2015
- CIK
- 0001228627
- Website
- opusgtx.com
- Similar Companies
- Business
- Opus Genetics, Inc. is a leading clinical-stage biopharmaceutical firm dedicated to pioneering advanced therapeutic solutions for patients grappling with inherited retinal diseases and various other ophthalmic conditions. The company’s robust pipeline prominently features adeno-associated virus (AAV)-based gene therapies, including its primary candidate, OPGx-LCA5, which has demonstrated promising early visual improvements in a Phase 1/2 clinical trial for Leber congenital amaurosis type 5 and is progressing towards a pivotal adaptive Phase 3 study. Another key gene therapy, OPGx-BEST1, designed for BEST1-related inherited retinal disease, recently commenced its Phase 1/2 clinical trial. Beyond gene therapies, Opus Genetics also offers Phentolamine Ophthalmic Solution, already approved for reversing pharmacologically induced mydriasis, and is evaluating it in late-stage Phase 3 trials for presbyopia and impaired dim light vision following keratorefractive surgery. Formerly operating as Ocuphire Pharma, Inc., the entity transformed into Opus Genetics, Inc. in October 2024 through an all-stock acquisition, signifying a strategic pivot towards gene therapy development. The company continues to advance a diverse portfolio from its headquarters in Research Triangle Park, North Carolina.
Company News
Opus Genetics Announces FDA Approval of Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia
Opus Genetics Presents Positive Clinical Data from OPGx-BEST1 and OPGx-LCA5 Gene Therapy Programs at Retina in Rio 2026
Opus Genetics to Present at the Chardan Annual Healthcare Conference
Opus Genetics, Inc. (NASDAQ:IRD) Receives Consensus Recommendation of “Moderate Buy” from Brokerages
Squarepoint Ops LLC Takes $1.36 Million Position in Opus Genetics, Inc. $IRD
Opus Genetics: A Resounding Study Success Merits A Higher Valuation
Opus Genetics, Inc. (IRD) Discusses Topline Results From Cohort 1 of BEST1 Phase I/II Gene Therapy Trial Transcript
Gene Therapy at Lower Dose Shows Vision Improvements, Opus Genetics Says
Opus Genetics Announces Positive Low Dose Cohort 1 Data from Phase 1/2 Clinical Trial of OPGx-BEST1 and Successful FDA Type C Meeting with Potential Phase 3 Dosing in 2027
Analysts Set Opus Genetics, Inc. (NASDAQ:IRD) PT at $10.69
Opus Genetics to Present OPGx-BEST1 Cohort 1 Clinical Data in Investor Webcast and at Upcoming Leading Ophthalmology Conferences
ADAR1 Capital Management LLC Takes $7.33 Million Position in Opus Genetics, Inc. $IRD
Opus Genetics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Opus Genetics, Inc. (IRD) Reports Q2 Loss, Lags Revenue Estimates
Opus Genetics Completes Patient Enrollment in Registrational Phase 3 Trial of OPGx-LCA5 for LCA5-Associated Inherited Retinal Disease
Opus Genetics Provides BEST1 Program Update with Detailed Timeline for OPGx-BEST1 Results
Opus Genetics Announces FDA Alignment on Phase 3 Registrational Trial Design for OPGx-LCA5 in LCA5-Associated Inherited Retinal Disease
Opus Genetics Added to the Russell 3000®, Russell 2000® and Russell Microcap® Indexes
Opus Genetics, Inc. (IRD) Discusses Early-Stage Gene Therapy Programs and Clinical Strategies for Inherited Retinal Diseases Transcript
Opus Genetics Highlights Five Gene Therapy Programs Targeting Significant Unmet Need in Patients with Inherited Retinal Diseases